Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 23 Carcinoma, Non-Small-Cell Lung 12 Colorectal Neoplasms 8 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Mesothelioma, Malignant 5 Melanoma 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Mesothelioma 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vascular Neoplasms 1 Uveal Melanoma 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 anlotinib 10 Temozolomide 10 Surgical Procedures, Operative 10 Sirolimus 10 camrelizumab 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × tremelimumab × Clear all

NCT03317457 2023-06-15

MEDISARC

AIO-Studien-gGmbH

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡